1.
Papp KA, Merola JF, Gottlieb AB, Griffiths CE, Harris KK, Cross N, Peterson L, Cioffi C, Blauvelt A. Bimekizumab provides rapid and sustained improvements in quality of life that correlate with clinical outcomes in patients with moderate to severe plaque psoriasis: 60 week results from a randomized , double blinded , Phase 2b extension study. J of Skin [Internet]. 2019Nov.9 [cited 2024Mar.28];3:S35. Available from: https://www.jofskin.org/index.php/skin/article/view/762